Experimental injection targets deadly brain cancer in early trial

NCT ID NCT07560865

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called FT536 for adults with a severe type of brain cancer (WHO Grade 4 astrocytoma) that has come back. The drug is injected directly into the tumor during surgery. The main goal is to check safety and find the right dose in 9 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) Disease Progression glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Elizabeth C. Neil, MD

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••